Study Title:
Phase I/II Study of Nivolumab in Combination with Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma: BTCRC-HEM15-027
 

• Open to Accrual at:
  • Masonic Cancer Center, University of Minnesota
  • University of Wisconsin Carbone Cancer Center
• Closed to Accrual at:
  • Holden Comprehensive Cancer Center, University of Iowa
• Learn more:
  • clinicaltrials.gov: NCT03681561
  • Big Ten CRC News Release

Study Contact: studies@hoosiercancer.org; (317) 921-2050.